<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/C0805014-A6FD-41C1-81BE-B94AE4139F25"><gtr:id>C0805014-A6FD-41C1-81BE-B94AE4139F25</gtr:id><gtr:name>Max Planck Society</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/48990B2D-6D88-4205-B3F4-58863EA78D0D"><gtr:id>48990B2D-6D88-4205-B3F4-58863EA78D0D</gtr:id><gtr:name>National Institute of Health and Medical Research (INSERM)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/5D55E165-233B-426B-B629-5FFC887C1004"><gtr:id>5D55E165-233B-426B-B629-5FFC887C1004</gtr:id><gtr:name>MRC Technology (MRCT)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/C3992259-C19F-4FE5-9C01-210C819D7264"><gtr:id>C3992259-C19F-4FE5-9C01-210C819D7264</gtr:id><gtr:name>Yale University</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:department>Medical and Human Sciences</gtr:department><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/C0805014-A6FD-41C1-81BE-B94AE4139F25"><gtr:id>C0805014-A6FD-41C1-81BE-B94AE4139F25</gtr:id><gtr:name>Max Planck Society</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/48990B2D-6D88-4205-B3F4-58863EA78D0D"><gtr:id>48990B2D-6D88-4205-B3F4-58863EA78D0D</gtr:id><gtr:name>National Institute of Health and Medical Research (INSERM)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/5D55E165-233B-426B-B629-5FFC887C1004"><gtr:id>5D55E165-233B-426B-B629-5FFC887C1004</gtr:id><gtr:name>MRC Technology (MRCT)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/C3992259-C19F-4FE5-9C01-210C819D7264"><gtr:id>C3992259-C19F-4FE5-9C01-210C819D7264</gtr:id><gtr:name>Yale University</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/8DC6E18C-A3C6-45A6-8EFF-BD1BD3A79D19"><gtr:id>8DC6E18C-A3C6-45A6-8EFF-BD1BD3A79D19</gtr:id><gtr:firstName>Royston</gtr:firstName><gtr:surname>Goodacre</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/8B8EA445-E75D-4708-972F-A10DF88F5961"><gtr:id>8B8EA445-E75D-4708-972F-A10DF88F5961</gtr:id><gtr:firstName>Douglas</gtr:firstName><gtr:otherNames>Bruce</gtr:otherNames><gtr:surname>Kell</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/C93EEE7C-E578-4F4A-97A8-95989028F2ED"><gtr:id>C93EEE7C-E578-4F4A-97A8-95989028F2ED</gtr:id><gtr:firstName>Ludwig</gtr:firstName><gtr:surname>Neyses</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0802004"><gtr:id>C0A94614-0117-4F09-82EE-A376AE90492E</gtr:id><gtr:title>The sarcolemmal calcium signalling protein PMCA4 as a novel target to reduce cardiac hypertrophy and failure</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0802004</gtr:grantReference><gtr:abstractText>Heart failure affects nearly 1 million people in the UK alone. Heart failure is a condition in which the heart can no longer supply the tissues of the body with enough blood to meet its metabolic demands. Despite recent progress in the treatment of this condition prognosis remains very poor, with 2-5% of the population likely to die from heart failure. It is therefore essential that we understand how and why this condition develops in order to develop better treatment strategies. Heart failure develops following an insult to the heart such as high blood pressure or a heart attack, this will lead to enlargement of the heart muscle, known as hypertrophy, before progressing to heart failure.
As a result of previous funding from the MRC we have determined that by deleting the plasma membrane calcium pump (PMCA4) gene from the cells of the heart in a mouse model that we can protect the heart from developing hypertrophy (muscle enlargement) and ultimately heart failure.
In the proposed programme of work we aim to determine how and why deletion of PMCA4 protects the heart from hypertrophy and heart failure. We will also determine whether this gene is involved in the development of disease in heart failure patients. In the future it may be possible to treat heart failure patients with a drug to stop the action of the PMCA4 protein and therefore protect these patients from heart failure; in this project we will take the first steps to identify a substance which would have this desired effect.</gtr:abstractText><gtr:technicalSummary>Heart Failure (HF) is one of the most prevalent causes of mortality globally, but its mechanisms are incompletely understood and treatment remains unsatisfactory. As a result of our MRC funded work on the mechanisms of calcium signalling in HF (Int. Appointee Grant, 2002-5, and subsequent programme grant, 2006-9) we have shown that the Plasma Membrane Calmodulin-dependent Calcium ATPase (PMCA4), whose role had been unknown, has a major role in physiological cardiac signalling by regulating neuronal NOS and the beta-adrenergic response. We have recently made the key finding that deletion of PMCA4 in vivo completely abolishes the pathological cardiac hypertrophic response, which underlies the development of HF. 
The present programme will: 
A. Start to define the mechanisms through which deletion of PMCA4 abolishes pathological cardiac hypertrophy and failure. 
B. Start to define the role of PMCA4 in human cardiac pathophysiology. 
C. Generate and initially test PMCA4 inhibitors. 
The results will: 
? Assign, for the first time, a specific signalling role to a cardiac membrane calcium transport system, i.e. PMCA4, in cardiac hypertrophy. This work will considerably increase our understanding of the mechanistic basis for calcium signalling in the normal and failing heart. 
? Provide evidence for the translation of these findings to human heart failure.
? Provide key tools that are currently not available for calcium research in the heart and in other fields, i.e. inhibitors with preferential specificity for PMCA4. This will lay the basic science foundations for potential future medical use of PMCA4 inhibitors in heart failure thus considerably narrowing the ?early funding gap? between basic science and translation into application, a major goal of MRC research funding.</gtr:technicalSummary><gtr:fund><gtr:end>2012-12-31</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2010-01-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>580001</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>MRC Technology (MRCT)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>PMCA4 drug inhibitor discovery</gtr:description><gtr:id>CA5B6368-342D-4F80-A377-5F99F04A00B8</gtr:id><gtr:impact>-</gtr:impact><gtr:partnerContribution>Know-how</gtr:partnerContribution><gtr:piContribution>Research materials and know-how</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Institute of Health and Medical Research (INSERM)</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:description>PMCA4 and malaria</gtr:description><gtr:id>97EEEFC5-6BC9-48AA-AC81-B878959E8C20</gtr:id><gtr:impact>-</gtr:impact><gtr:partnerContribution>-</gtr:partnerContribution><gtr:piContribution>PMCA4 knockout mice</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Max Planck Society</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:department>Bonn</gtr:department><gtr:description>novel contraception method</gtr:description><gtr:id>687A591F-2A81-4C70-BF98-19CA201B741A</gtr:id><gtr:impact>In October 2010 we obtained a Bill Gates grant (funding rate 2.5% of all applications) to further develop this idea. 
This collaboration is highly multidisciplinary (biochemistry, molecular biology, sperm physiology, biomaterial research). It involves the MRC Fertility Research Centre in Edinburgh, the Max-Planck Institute in Bonn, the University Centre of Andrology in Munster, Germany and the European Screening Port in Hamburg.</gtr:impact><gtr:partnerContribution>The MPI in Bonn is world-leading in sperm physiology, our group is world-leading in PMCA4 research. Together with the MPI we are currently developing a novel method for local contraception. Another major partner is Prof. Nicola Tirelli, Manchester, who is developing the biomaterials/ microcarriers that will carry the inhibitor substance.</gtr:partnerContribution><gtr:piContribution>In our MRC-funded research we found that animals carrying a gene deletion for a calcium pump (called PMCA4) had a cardiac phenotype, but in addition, male animals were infertile due to a sperm motililty defect. This lead to the idea that inhibitors of PMCA4 could be used for contraception. This is a classical example of translation by serendipity and lateral thinking (contraception project from a cardiology research group!)</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Yale University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>PMCA4 and epithelial and endothelial cells</gtr:description><gtr:id>E308B600-60DA-4A59-9C3A-92DB42B1B0B6</gtr:id><gtr:impact>-</gtr:impact><gtr:partnerContribution>-</gtr:partnerContribution><gtr:piContribution>inhibitor and PMCA4 knockout mice</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>AHA Congress, Dallas</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>86DD8CEB-8DAE-430E-B004-80FC4D59BB9C</gtr:id><gtr:impact>recognition for the University

-</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Press release</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>78CBEF32-DEB2-40B6-B8C7-E6D5A568592E</gtr:id><gtr:impact>The press release was widely read and lead to multiple phone calls/ emails from newspapers and weekly magazines (e.g. TIME).

see above</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Newspaper article</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>EBA1F4ED-6CF3-4510-89C6-89094FBB32DE</gtr:id><gtr:impact>Article appeared in Manchester Evening News, Businnes and Innovation section

not applicable</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Manchester Science Festival Week at the Manchester Museum</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>EFB73337-53C1-4E96-9832-A3EA4053302E</gtr:id><gtr:impact>Great numbers of public of all ages attended the Festival, watched demonstrations of an ECG, of hearts from different species, models of the cardiovascular system, etc. The feedback from the public was fantastic.

unknown</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2011,2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Assessment of the ffect of laughing in blood pressure/laughter yoga workshop</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>27939F78-830F-44CF-A4A0-BC19018EFA38</gtr:id><gtr:impact>....

.....</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Sixth form students visit to the lab</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>E07C9831-6A64-48FE-9577-CE2B88902C72</gtr:id><gtr:impact>A group of sixth form students visited the lab to observe beating cardiomyocytes, measure blood pressure and ECG, the pathology of heart disease and the mechenisms of heart failure.

One of the students will decided to do a summer project in the lab.</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>59800</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>A metabolic analysis of adverse cardiac remodelling following myocardial infarction; a first step towards identification of a clinical biomarker</gtr:description><gtr:end>2010-12-02</gtr:end><gtr:fundingOrg>Johnson &amp; Johnson</gtr:fundingOrg><gtr:id>27C4FBA1-BDC9-4BE9-A95B-095F64ADE45B</gtr:id><gtr:sector>Private</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>9800</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>National Institute for Health Research (NIHR)</gtr:department><gtr:description>Markers of Adverse LV remodelling using Serum metabolomics/Central Manchester University Hospital Foundation Trust</gtr:description><gtr:end>2012-12-02</gtr:end><gtr:fundingOrg>University College London Hospitals Charity (UCLH)</gtr:fundingOrg><gtr:id>BF7B7700-298A-4E4E-8D8D-2ADB420D1053</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>100000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Bill Gates award, Grand Challenges scheme</gtr:description><gtr:end>2012-12-02</gtr:end><gtr:fundingOrg>Bill and Melinda Gates Foundation</gtr:fundingOrg><gtr:id>51DA419F-8A2F-449A-85A8-7A1E02706191</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>The invention relates to the use of plasma membrane calcium ATPase (PMCA) inhibitors for inhibiting sperm mobility to achieve a contraceptive effect. The invention further relates to to contraceptive agents comprising one or more PMCA inhibitors.</gtr:description><gtr:id>F2281A24-73E7-4B17-A4F2-870C831C4B2A</gtr:id><gtr:impact>unknown</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:patentId>WO2005002495</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Methods of Diagnosing Infertility by detecting PMCA4 Mutations</gtr:title></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>In our MRC-funded research we found that animals carrying a gene deletion for a calcium pump (called PMCA4) had a cardiac phenotype, but in addition, male animals were infertile due to a sperm motililty defect. This led to the idea that inhibitors of PMCA4 could be used for contraception. This is a classic example of translation by serendipity and lateral thinking (contraception project from a cardiology research group!)</gtr:description><gtr:id>147890B4-99DF-4932-8D79-72C5EE45DAAF</gtr:id><gtr:impact>Following the award from the Bill Gates foundation, the IP for this invention was made available to the BG foundation by the University of Manchester</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:patentId>US2006276529</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Use of PMCA4 inhibitor for non-hormonal contraception</gtr:title><gtr:yearProtectionGranted>2006</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Guidelines on ACS of the European Society of Cardiology</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>CEC1ED41-CC03-4EE9-B10A-940F577BC8C3</gtr:id><gtr:impact>The costs for heart failure druges/devices and hospitalisation as well as chronic care are in the order of 10 billion Euros per year (plus &amp;pound;1 billion for the UK). Care delivery at each stage is critically influenced by the guidelines which are written/ reviewed by the Board members of the Heart Failure Association of the European Society of Cardiology. My Board membership was only possible as a result of my MRC funded research (as the nomination/election process was very competitive, 2 out of 80 candidates were selected).</gtr:impact><gtr:type>Membership of a guidance committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:description>The product will be a highly adhesive vaginal gel containing PMCA4 inhibitors to produce long-term local contraception.</gtr:description><gtr:id>CEB57ECC-901F-4D49-8D4D-70A5274FF46C</gtr:id><gtr:impact>The product will be extremely inexpensive and therefore be ideal for use in poor countries - in accordance with the priorities of the Bill and Melinda Gates foundation.</gtr:impact><gtr:stage>Refinement.  Non-clinical</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>PMCA4 inhibitor for non-hormonal contraception</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2010</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Transgenic mouse overexpressing PMCA4 specifically in the heart. Mouse line has been generated and characterised (see Oceandy et al 2007).</gtr:description><gtr:id>8D5B1954-316A-4B69-925C-31B6751ED634</gtr:id><gtr:impact>Transgenic mouse overexpressing PMCA4 specifically in the heart. Mouse line has been generated and characterised (see Oceandy et al 2007).</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>PMCA4 TG</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>PMCA4 knockout mouse line. Generated by homologous recombination in ES cells (see Schuh et al 2004). Mouse line has been generated and characerised in terms of male fertility phenotype, this data is publically available. Characterisation of cardiac phenotype is ongoing. Took 2.5 years to develop and establish the PCA4 knock-ut line. 2 years to chracterise male fertility phenotype.</gtr:description><gtr:id>9F28EAEA-C23D-49C6-8E2E-E088817B249B</gtr:id><gtr:impact>GIVEN TO 5 RESEARCH GROUPS</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>PMCA4 KO</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type><gtr:yearFirstProvided>2007</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Mouse model to determine role of PMCA in the heart. This proved key in understanding heart hypertrophy and failure (PMCA4 knock-out animals do not develop pathological hypertrophy)</gtr:description><gtr:id>00083271-A2FB-43D2-8C48-AC27FA1AED47</gtr:id><gtr:impact>We have started to develop a PMCA 4 inhibitor which might then be able to be developed into an antihypertrophic drug.</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>PMCA in the heart</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type><gtr:yearFirstProvided>2006</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>The mice carry a genetic deletion for the isoform 1 of the plasma membrane calcium pump. A polymorphism in this gene has recently been shown to be the strongest genetic predictor of high blood pressure, which is prevalent in over 80% of patients with heart failure. Therefore, these animals are a unique tool to study the mechanisms of high blood pressure and heart failure.</gtr:description><gtr:id>1424A07A-A6D7-41FA-8428-74B34371C980</gtr:id><gtr:impact>This research is key in providing a mechanistic understanding of the genetic basis underlying high blood pressure, the most prevalent risk factor for stroke and heart failure as well as one of the commonest conditions underlying kidney failure and heart attacks. It also provides a novel target for drug therapy.</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>PMCA1 knock-out animals</gtr:title><gtr:type>Model of mechanisms or symptoms - human</gtr:type><gtr:yearFirstProvided>2010</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Mouse model of hypertrophy</gtr:description><gtr:id>E54ABAF8-9355-45B5-A6C0-1196142804E0</gtr:id><gtr:impact>on going</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>PMCA4 Cardiac specific knock-out</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A86F3942-D0BF-4351-B1C4-779AB2F4C4E5"><gtr:id>A86F3942-D0BF-4351-B1C4-779AB2F4C4E5</gtr:id><gtr:title>Disruption of the interaction between PMCA2 and calcineurin triggers apoptosis and enhances paclitaxel-induced cytotoxicity in breast cancer cells.</gtr:title><gtr:parentPublicationTitle>Carcinogenesis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/cd5a2205be0823bf4a0d59146c0b92f6"><gtr:id>cd5a2205be0823bf4a0d59146c0b92f6</gtr:id><gtr:otherNames>Baggott RR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0143-3334</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/25DEA294-54E3-4D3C-B28A-038AD7A3064C"><gtr:id>25DEA294-54E3-4D3C-B28A-038AD7A3064C</gtr:id><gtr:title>Targeted deletion of the extracellular signal-regulated protein kinase 5 attenuates hypertrophic response and promotes pressure overload-induced apoptosis in the heart.</gtr:title><gtr:parentPublicationTitle>Circulation research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ce4fda1a36c3846dd1e93f99db3b8ab2"><gtr:id>ce4fda1a36c3846dd1e93f99db3b8ab2</gtr:id><gtr:otherNames>Kimura TE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0009-7330</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6DC1881B-9634-4EBF-84F2-5C514169008A"><gtr:id>6DC1881B-9634-4EBF-84F2-5C514169008A</gtr:id><gtr:title>Pak1 as a novel therapeutic target for antihypertrophic treatment in the heart.</gtr:title><gtr:parentPublicationTitle>Circulation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c14bc14b523f46259b756e82875d7f82"><gtr:id>c14bc14b523f46259b756e82875d7f82</gtr:id><gtr:otherNames>Liu W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0009-7322</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/70658B86-AB1B-478C-BE84-A9F70D413B3E"><gtr:id>70658B86-AB1B-478C-BE84-A9F70D413B3E</gtr:id><gtr:title>Endothelial nitric oxide synthase activity is inhibited by the plasma membrane calcium ATPase in human endothelial cells.</gtr:title><gtr:parentPublicationTitle>Cardiovascular research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9772ee5f2688407a41dea655589c3af9"><gtr:id>9772ee5f2688407a41dea655589c3af9</gtr:id><gtr:otherNames>Holton M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0008-6363</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7EEC5561-4F30-49E8-91B3-241564F28AAB"><gtr:id>7EEC5561-4F30-49E8-91B3-241564F28AAB</gtr:id><gtr:title>Local signals with global impacts and clinical implications: lessons from the plasma membrane calcium pump (PMCA4).</gtr:title><gtr:parentPublicationTitle>Biochimica et biophysica acta</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f71a9e429f5224f14b1bfea4f436643e"><gtr:id>f71a9e429f5224f14b1bfea4f436643e</gtr:id><gtr:otherNames>Oceandy D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0006-3002</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/3DEB609F-66E4-4F4A-ADEF-298A4E49E95B"><gtr:id>3DEB609F-66E4-4F4A-ADEF-298A4E49E95B</gtr:id><gtr:title>Calcium signaling dysfunction in heart disease.</gtr:title><gtr:parentPublicationTitle>BioFactors (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e5082d72d197846975ebcb9553432d32"><gtr:id>e5082d72d197846975ebcb9553432d32</gtr:id><gtr:otherNames>Cartwright EJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0951-6433</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/54A5DC95-330F-4B92-91C9-C06E684AB1F7"><gtr:id>54A5DC95-330F-4B92-91C9-C06E684AB1F7</gtr:id><gtr:title>The plasma membrane calcium ATPase 4 signalling in cardiac fibroblasts mediates cardiomyocyte hypertrophy.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8a3b91614947e6fb9c73d10d48dc7fb6"><gtr:id>8a3b91614947e6fb9c73d10d48dc7fb6</gtr:id><gtr:otherNames>Mohamed TM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/97CB0E80-8D51-49F1-B715-D9A3AB90C7DD"><gtr:id>97CB0E80-8D51-49F1-B715-D9A3AB90C7DD</gtr:id><gtr:title>Role of advanced glycation end products in cardiovascular disease.</gtr:title><gtr:parentPublicationTitle>World journal of cardiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4611225f589c631efa432e133805cafc"><gtr:id>4611225f589c631efa432e133805cafc</gtr:id><gtr:otherNames>Hegab Z</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/64D4CA81-F9C8-4013-AF75-360ADFF1F568"><gtr:id>64D4CA81-F9C8-4013-AF75-360ADFF1F568</gtr:id><gtr:title>Deprivation of MKK7 in cardiomyocytes provokes heart failure in mice when exposed to pressure overload.</gtr:title><gtr:parentPublicationTitle>Journal of molecular and cellular cardiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c14bc14b523f46259b756e82875d7f82"><gtr:id>c14bc14b523f46259b756e82875d7f82</gtr:id><gtr:otherNames>Liu W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-2828</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/CDB68498-1108-4919-97CB-05E366872084"><gtr:id>CDB68498-1108-4919-97CB-05E366872084</gtr:id><gtr:title>Plasma membrane calcium pump (PMCA4)-neuronal nitric-oxide synthase complex regulates cardiac contractility through modulation of a compartmentalized cyclic nucleotide microdomain.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8a3b91614947e6fb9c73d10d48dc7fb6"><gtr:id>8a3b91614947e6fb9c73d10d48dc7fb6</gtr:id><gtr:otherNames>Mohamed TM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D9112BE7-91B1-4CEE-8A40-B81B154EA10B"><gtr:id>D9112BE7-91B1-4CEE-8A40-B81B154EA10B</gtr:id><gtr:title>The plasma membrane calcium ATPase modulates calcium homeostasis, intracellular signaling events and function in platelets.</gtr:title><gtr:parentPublicationTitle>Journal of thrombosis and haemostasis : JTH</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6f76a7f265485c2dbe40074d7948aa66"><gtr:id>6f76a7f265485c2dbe40074d7948aa66</gtr:id><gtr:otherNames>Jones S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1538-7836</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/62C05F21-6DDF-483A-8787-69BB88CE0CBE"><gtr:id>62C05F21-6DDF-483A-8787-69BB88CE0CBE</gtr:id><gtr:title>Mitogen-activated protein kinase kinase 4 deficiency in cardiomyocytes causes connexin 43 reduction and couples hypertrophic signals to ventricular arrhythmogenesis.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/776db90b25d4f70bab385d60fac223db"><gtr:id>776db90b25d4f70bab385d60fac223db</gtr:id><gtr:otherNames>Zi M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/54577309-E526-41F7-B62F-67A77C391B18"><gtr:id>54577309-E526-41F7-B62F-67A77C391B18</gtr:id><gtr:title>Evaluation of plasma membrane calcium/calmodulin-dependent ATPase isoform 4 as a potential target for fertility control.</gtr:title><gtr:parentPublicationTitle>Handbook of experimental pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e5082d72d197846975ebcb9553432d32"><gtr:id>e5082d72d197846975ebcb9553432d32</gtr:id><gtr:otherNames>Cartwright EJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0171-2004</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/85402B81-6CEB-4767-9DFC-288E5825CFB6"><gtr:id>85402B81-6CEB-4767-9DFC-288E5825CFB6</gtr:id><gtr:title>Calcium Extrusion Pump PMCA4: A New Player in Renal Calcium Handling?</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/66a9038d4ff73f58094817bb96b2322c"><gtr:id>66a9038d4ff73f58094817bb96b2322c</gtr:id><gtr:otherNames>van Loon EP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/222475F5-6FAA-4881-8372-EF3E18395C5B"><gtr:id>222475F5-6FAA-4881-8372-EF3E18395C5B</gtr:id><gtr:title>Development and characterization of a novel fluorescent indicator protein PMCA4-GCaMP2 in cardiomyocytes.</gtr:title><gtr:parentPublicationTitle>Journal of molecular and cellular cardiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8a3b91614947e6fb9c73d10d48dc7fb6"><gtr:id>8a3b91614947e6fb9c73d10d48dc7fb6</gtr:id><gtr:otherNames>Mohamed TM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-2828</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/75483E7C-58AE-4AC8-A5B5-F81C2E0B4A8C"><gtr:id>75483E7C-58AE-4AC8-A5B5-F81C2E0B4A8C</gtr:id><gtr:title>Ca2+ signalling in cardiovascular disease: the role of the plasma membrane calcium pumps.</gtr:title><gtr:parentPublicationTitle>Science China. Life sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e5082d72d197846975ebcb9553432d32"><gtr:id>e5082d72d197846975ebcb9553432d32</gtr:id><gtr:otherNames>Cartwright EJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1674-7305</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9EAC10F5-880F-4FDD-84F1-0EB7DDB06506"><gtr:id>9EAC10F5-880F-4FDD-84F1-0EB7DDB06506</gtr:id><gtr:title>The tumour suppressor Ras-association domain family protein 1A (RASSF1A) regulates TNF-a signalling in cardiomyocytes.</gtr:title><gtr:parentPublicationTitle>Cardiovascular research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8a3b91614947e6fb9c73d10d48dc7fb6"><gtr:id>8a3b91614947e6fb9c73d10d48dc7fb6</gtr:id><gtr:otherNames>Mohamed TM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0008-6363</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0802004</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>D4FDB752-4E9C-491F-9C63-B7D7F6F95417</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cardiovascular</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>